145 related articles for article (PubMed ID: 18157792)
1. The counsellees' view of an unclassified variant in BRCA1/2: recall, interpretation, and impact on life.
Vos J; Otten W; van Asperen C; Jansen A; Menko F; Tibben A
Psychooncology; 2008 Aug; 17(8):822-30. PubMed ID: 18157792
[TBL] [Abstract][Full Text] [Related]
2. Perceiving cancer-risks and heredity-likelihood in genetic-counseling: how counselees recall and interpret BRCA 1/2-test results.
Vos J; Oosterwijk JC; Gómez-García E; Menko FH; Jansen AM; Stoel RD; van Asperen CJ; Tibben A; Stiggelbout AM
Clin Genet; 2011 Mar; 79(3):207-18. PubMed ID: 21114486
[TBL] [Abstract][Full Text] [Related]
3. Opening the psychological black box in genetic counseling. The psychological impact of DNA testing is predicted by the counselees' perception, the medical impact by the pathogenic or uninformative BRCA1/2-result.
Vos J; Gómez-García E; Oosterwijk JC; Menko FH; Stoel RD; van Asperen CJ; Jansen AM; Stiggelbout AM; Tibben A
Psychooncology; 2012 Jan; 21(1):29-42. PubMed ID: 21072753
[TBL] [Abstract][Full Text] [Related]
4. Patients with an unclassified genetic variant in the BRCA1 or BRCA2 genes show different clinical features from those with a mutation.
Gómez-García EB; Ambergen T; Blok MJ; van den Wijngaard A
J Clin Oncol; 2005 Apr; 23(10):2185-90. PubMed ID: 15800311
[TBL] [Abstract][Full Text] [Related]
5. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J
Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254
[TBL] [Abstract][Full Text] [Related]
6. Subjective interpretation of inconclusive BRCA1/2 cancer genetic test results and transmission of information to the relatives.
Cypowyj C; Eisinger F; Huiart L; Sobol H; Morin M; Julian-Reynier C
Psychooncology; 2009 Feb; 18(2):209-15. PubMed ID: 19061202
[TBL] [Abstract][Full Text] [Related]
7. Screening BRCA1 and BRCA2 unclassified variants for splicing mutations using reverse transcription PCR on patient RNA and an ex vivo assay based on a splicing reporter minigene.
Bonnet C; Krieger S; Vezain M; Rousselin A; Tournier I; Martins A; Berthet P; Chevrier A; Dugast C; Layet V; Rossi A; Lidereau R; Frébourg T; Hardouin A; Tosi M
J Med Genet; 2008 Jul; 45(7):438-46. PubMed ID: 18424508
[TBL] [Abstract][Full Text] [Related]
8. A randomized trial of a breast/ovarian cancer genetic testing decision aid used as a communication aid during genetic counseling.
Wakefield CE; Meiser B; Homewood J; Taylor A; Gleeson M; Williams R; Tucker K;
Psychooncology; 2008 Aug; 17(8):844-54. PubMed ID: 18613319
[TBL] [Abstract][Full Text] [Related]
9. Using genetic analysis to individualize preventive measures for breast and ovarian cancers.
Olopade OI
Nat Clin Pract Oncol; 2006 Apr; 3(4):182-3. PubMed ID: 16596140
[No Abstract] [Full Text] [Related]
10. Influence of race/ethnicity on genetic counseling and testing for hereditary breast and ovarian cancer.
Forman AD; Hall MJ
Breast J; 2009; 15 Suppl 1():S56-62. PubMed ID: 19775331
[TBL] [Abstract][Full Text] [Related]
11. Receiving inconclusive genetic test results: an interpretive description of the BRCA1/2 experience.
Maheu C; Thorne S
Res Nurs Health; 2008 Dec; 31(6):553-62. PubMed ID: 18449940
[TBL] [Abstract][Full Text] [Related]
12. One risk fits all?
De Bock GH; Mourits MJ; Oosterwijk JC
J Clin Oncol; 2007 Aug; 25(22):3383-4; author reply 3384. PubMed ID: 17664491
[No Abstract] [Full Text] [Related]
13. Recall of and reactions to a surgeon referral letter for BRCA genetic counseling among high-risk breast cancer patients.
Vadaparampil ST; Quinn GP; Miree CA; Brzosowicz J; Carter B; Laronga C
Ann Surg Oncol; 2009 Jul; 16(7):1973-81. PubMed ID: 19408048
[TBL] [Abstract][Full Text] [Related]
14. [Information spreading about hereditary carriage of a BRCA1/2 mutation and ovarian cancer and rate of consultation of the concerned relatives].
Christophe V; Leroy T; Adenis C; Reich M; Vennin P
Bull Cancer; 2008 Apr; 95(4):395-402. PubMed ID: 18495568
[TBL] [Abstract][Full Text] [Related]
15. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
16. Hereditary breast and ovarian cancer syndrome.
ACOG Committee on Practice Bulletins
Gynecol Oncol; 2009 Apr; 113(1):6-11. PubMed ID: 19309638
[No Abstract] [Full Text] [Related]
17. Genetic counseling does not fulfill the counselees' need for certainty in hereditary breast/ovarian cancer families: an explorative assessment.
Vos J; Menko FH; Oosterwijk JC; van Asperen CJ; Stiggelbout AM; Tibben A
Psychooncology; 2013 May; 22(5):1167-76. PubMed ID: 22777929
[TBL] [Abstract][Full Text] [Related]
18. BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark.
Soegaard M; Kjaer SK; Cox M; Wozniak E; Høgdall E; Høgdall C; Blaakaer J; Jacobs IJ; Gayther SA; Ramus SJ
Clin Cancer Res; 2008 Jun; 14(12):3761-7. PubMed ID: 18559594
[TBL] [Abstract][Full Text] [Related]
19. BRCA1 p.Val1688del is a deleterious mutation that recurs in breast and ovarian cancer families from Northeast Italy.
Malacrida S; Agata S; Callegaro M; Casella C; Barana D; Scaini MC; Manoukian S; Oliani C; Radice P; Barile M; Menin C; D'Andrea E; Montagna M
J Clin Oncol; 2008 Jan; 26(1):26-31. PubMed ID: 18165637
[TBL] [Abstract][Full Text] [Related]
20. [Cancer genetics: estimation of the needs of the population in France for the next ten years].
Bonaïti-Pellié C; Andrieu N; Arveux P; Bonadona V; Buecher B; Delpech M; Jolly D; Julian-Reynier C; Luporsi E; Noguès C; Nowak F; Olschwang S; Orsi F; Pujol P; Saurin JC; Sinilnikova O; Stoppa-Lyonnet D; Thépot F
Bull Cancer; 2009 Sep; 96(9):875-900. PubMed ID: 19751997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
